BioPharmaDive

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated "triple-G" weight loss medicine.

Results from a late-stage study focused on generalized anxiety disorder were a "clean win" to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Some analysts believe Silence's polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

Vykat XR, a newly approved drug sold by Neurocrine Biosciences, is possibly tied to a series of deaths and cases of severe side effects, experts say.

Doctors and other experts say that splitting the measles, mumps and rubella shot has no scientific basis and is unlikely to get off the ground.

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more "high-potential" medicines.

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.